Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - LogicBio Therapeutics, Inc. | logc-ex321_7.htm |
| EX-31.2 - EX-31.2 - LogicBio Therapeutics, Inc. | logc-ex312_15.htm |
| EX-31.1 - EX-31.1 - LogicBio Therapeutics, Inc. | logc-ex311_14.htm |
| EX-21.1 - EX-21.1 - LogicBio Therapeutics, Inc. | logc-ex211_9.htm |
| EX-10.22 - EX-10.22 - LogicBio Therapeutics, Inc. | logc-ex1022_66.htm |
| EX-10.6 - EX-10.6 - LogicBio Therapeutics, Inc. | logc-ex106_67.htm |
| 10-K - 10-K - LogicBio Therapeutics, Inc. | logc-10k_20201231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-234735 on Form S-3 and Registration Statement No. 333-237238 and 333-230689 on Form S-8 of our report dated March 15, 2021, relating to the financial statements of LogicBio Therapeutics, Inc. appearing in this Annual Report on Form 10-K of LogicBio Therapeutics, Inc. for the year ended December 31, 2020.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 15, 2021